Antibody Response of Dogs After Immunisation with Chimeric Vaccine Against Borreliosis  by Nepereny, J. et al.
 Procedia in Vaccinology  9 ( 2015 )  31 – 34 
1877-282X © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Selection and peer-review under responsibility of the 8th Vaccine Conference Organizing Committee.
doi: 10.1016/j.provac.2015.05.005 
Available online at www.sciencedirect.com
ScienceDirect
8th Vaccine & ISV Congress, Philadelphia, USA, 2015 
Antibody response of dogs after immunisation with chimeric 
vaccine against borreliosis 
Nepereny, J.a, Vrzal, V.a, Raska, M.b, Weigl, E.b, Krupka, M.b, Turanek, J.c, Masek, J.c 
a  Bioveta, a. s., Komenskeho 212, 683 23 Ivanovice na Hane, Czech Republic 
b Faculty of Medicine and Dentistry, Palacky University Olomouc, Trida Svobody 8, 771 26 Olomouc, Czech Republic  
c  Veterinary research institute, Hudcova 296/70, 621 00 Brno, Czech Republic 
  
Abstract 
Two chimeric recombinant fusion proteins (ch-rOspC and ch-rOspA) were created. They are composed of the 
immunodominant domains of OspC and OspA proteins described in the clinically most important strains of Borrelia. 
The gene constructs for these chimeric proteins were inserted into plasmids pET28 allowing induced gene 
expressions in a bacterial system. 
The proteins were expressed in E. coli BL21 strains, purified and used for preparation of the vaccine.  
One dose of the tested vaccines contained 50 μg of each relevant protein (ch-rOspC, ch-rOspA, or ch-rOspC+ch-
rOspA). PET GEL A (Seppic) or Aluminium hydroxide gel as the immune adjuvants were used. 
The dogs were vaccinated three times at 21 days intervals subcutaneously or intradermally and unvaccinated 
controls were also included.  
The vaccine-elicited serum action antibodies specific to OspA and OspC were determined using in-house ELISA 
sets. 
The immunisation induced specific antibody response in the vaccinated animals and OspC and OspA from 
representative genospecies B. garinii, B. afzelii, and B. burgdorferi sensu stricto were recognized. The control dogs 
were without antibody response. 
ELISA examination enables determination of specific post-vaccination antibodies against OspA and OspC. 
Detection of these antibodies and their quantification may be used for evaluation of efficiency of vaccines. 
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1. INTRODUCTION 
Lyme disease is a chronic multisystem infectious disease that is the most common arthropod-borne infectious 
disease both in Europe and in the United States. The disease is caused by a group of spirochetes collectively known 
as Borrelia burgdorferi sensu lato. This group of microorganisms is composed of three closely related, most 
pathogenic subspecies - Borrelia burgorferi sensu stricto, Borrelia afzelii and Borrelia garinii. While B. burgdorferi 
sensu stricto is the cause of virtually all Lyme diseases in North America, B. garinii and B. afzelii prevail in 
Europe1. 
The existing problems in diagnosis and treatment of Lyme disease and inability to effectively control and reduce the 
distribution of borrelia vectors gave rise to an urgent need to manufacture a vaccine that would be capable to 
effectively immunize susceptible species of domestic animals, especially dogs, against infection with Borrelia 
burgdorferi sensu lato2, 3. 
Vaccines based on the whole-cell bacterin Borrelia burgdorferi were developed for use in domestic animals. Other 
developed vaccines were based on the content of OspA and OspC proteins or other outer surface immunogenic 
proteins isolated from borrelia cultures, expressed as recombinant proteins in different hosts (E. coli) or prepared 
synthetically. 
The contemporary experimental efforts are focused mainly on OspA and OspC antigens. The main reason is the 
possibility of using these antigens for vaccination purposes 4, 5, 6. 
 
2.  METHODS 
Two chimeric recombinant fusion proteins (ch-rOspC and ch-rOspA) were created. They are composed of the 
immunodominant domains of OspC and OspA proteins described in the clinically most important strains of Borrelia.  
These purified proteins were used for preparation of the vaccine.  
 
Table 1, Vaccination schedules 
Vaccination 
schedule Antigen 
Immune 
adjuvants Application 
Vaccination 1st revaccination 2nd revaccination 
Day 0 Day 26 Day 42 
1 rOspA+rOspC 50 μg + 50 μg Aluxid s.c. Antigen Antigen Antigen 
2 rOspA+rOspC 50 μg + 50 μg Aluxid i.d. Antigen Antigen Antigen 
3 rOspA+rOspC 50 μg + 50 μg PET GEL A s.c. Antigen Antigen Antigen 
4 rOspA+rOspC 50 μg + 50 μg PET GEL A i.d. Antigen Antigen Antigen 
5 - - Aluxid s.c. PLACEBO PLACEBO PLACEBO 
6 - - Aluxid i.d. PLACEBO PLACEBO PLACEBO 
7 - - PET GEL A s.c. PLACEBO PLACEBO PLACEBO 
8 - - PET GEL A i.d. PLACEBO PLACEBO PLACEBO 
 
The blood samples were taken in predetermined intervals and sera samples were prepared.  
The post-vaccination antibodies against OspA and OspC in the sera samples were detected using in-house indirect 
sandwich ELISA sets with highly purified specific recombinant protein7, 8. 
Antibody levels in the tested sera were expressed as an OD450 values, compared to the values of the control positive 
and negative sera. 
 
2.1 Substances for ELISA 
x Antigen coating (rOspA B. afzelii, rOspA B. garinii, rOspA B. burgdorferi sensu stricto, rOspC B. afzelii, 
rOspC B. garinii, rOspC B. burgdorferi sensu stricto) 
x Conjugate (Dog Immunoglobulin G (IgG) Goat anti-Dog Polyclonal (HRP) Antibody) 
x Control positive antisera (dog origin) 
(anti B. afzelii, anti B. garinii, anti B. burgdorferi sensu stricto) 
x Control negative serum (dog origin) 
x Washing solution (PBS pH 7.2 + TWEEN 20) 
x Blocking and dilution buffer (Skim milk + PBS pH 7.2 + TWEEN 20) 
x Substrate (Sodium acetate buffer + TMB working solution + distilled water + H2O2 30%) 
x Stop solution (H2SO4) 
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3. RESULTS 
The immunisation with recombinant chimeric proteins in conjunction with suitable immune adjuvant induced 
specific antibody response in the vaccinated animals and all three types (B. afzelii, B. garinii, B. burgdorferi sensu 
stricto) of OspA and OspC were recognized. The control dogs were without antibody response (graphs No. 1 – 6). 
Vaccination schedule involving primary vaccination + 2 revaccinations is good for induction of high specific 
antibody levels. Antibody levels declined gradually. The onset of antibody response against OspA and OspC 
antigens is slightly different.  
 
 
 
 
 
 
 
 
 
 
 
Graph 1, Antibody response OspA B. afzelii    Graph 2, Antibody response OspC B. afzelii  
 
 
 
 
 
 
 
 
 
 
 
Graph 3, Antibody response OspA B. garinii   Graph 4, Antibody response OspC B. garinii 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 5, Antibody response OspA B. burgdorferi s.s.   Graph 6, Antibody response OspC B. burgdorferi s.s. 
 
4. CONCLUSION 
The recombinant chimeric antigens contained in the vaccine are immunogenic and antibody response in the 
vaccinated animals is induced. 
ELISA examination enables determination of specific post-vaccination antibodies against OspA and OspC. 
Detection of these antibodies and their quantification may be used for evaluation of efficiency of vaccines and onset 
and duration of immunity. 
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